<DOC>
	<DOCNO>NCT00684203</DOCNO>
	<brief_summary>The study design assess safety effect vorapaxar , add standard care ( aspirin clopidigrel ) , Japanese subject acute coronary syndrome . The study may also provide information effect vorapaxar prevent heart attack stroke subject population .</brief_summary>
	<brief_title>Trial Assess Safety Effects Vorapaxar Japanese Subjects With Acute Coronary Syndrome ( P04772 ; MK-5348-016 )</brief_title>
	<detailed_description>The study drug ( load dose ) administer least 1 hour catheterization diagnostic image percutaneous coronary intervention ( PCI ) . The incidence bleed think important index assess safety drug , therefore thrombolysis myocardial infarction ( TIMI ) evaluate .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Vorapaxar</mesh_term>
	<criteria>Men woman age 18 year history cardiac ischemia relate chest discomfort &gt; 10 minute duration &lt; 24 hour prior randomization , least 1 follow A B . Participants plan undergo PCI target participant . A : Positive biomarkers [ Elevated troponin I creatinine kinase MB isozyme great site 's upper limit normal ( ULN ) ] registration B : Electrocardiogram ( ECG ) change : ST segment depression &gt; = 0.1 mV ( &gt; =1 mm ) , transient ( &lt; 30 minute ) ST segment elevation &gt; = 0.1 mV ( &gt; =1 mm ) least 2 contiguous lead Willing give appropriate inform consent complete studyrelated procedure , able adhere dose visit schedule . Women childbearing potential ( postmenarchal woman &lt; 1 year menopausal surgical sterilization hysterectomy consider woman childbearing potential ) must agree use medically accept method contraception receive protocolspecified medication , 60 day stop medication . Pregnant nursing mother ( premenopausal woman negative pregnancy test result confirm enrollment ) Any serious illness condition investigator feel would pose significant hazard participant investigational therapy initiate known hypersensitivity component current investigational product ; Participation study experimental therapy use investigational drug within 30 day enrollment Member staff personnel directly involve study ; Family member investigational study staff ; History bleed diathesis , evidence active abnormal bleeding within 30 day enrollment History hemorrhagic stroke time Severe hypertension ( systolic blood pressure &gt; 200 mm Hg diastolic blood pressure &gt; 110 mm Hg ) receive therapy ; Major surgery within 2 week prior enrollment Known platelet count &lt; 100,000/mm^3 Uncontrolled cardiac arrhythmia ; Known impairment renal function ( serum creatinine &gt; 2.0 mg/dL [ &gt; 176.8 umol/L ] ) , dysproteinemia , nephrotic syndrome , renal disease ; Active chronic hepatobiliary hepatic disease , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) activity two time great upper limit laboratory reference range Anticipated stag PCI Concurrent anticipate treatment warfarin , factor Xa inhibitor , direct thrombin inhibitor , antiplatelet agent except aspirin ticlopidine enrollment Anticipated intracoronary brachytherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>